John Kersey

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi request reprint Blood and marrow transplantation: a perspective from the University of Minnesota
    John H Kersey
    Department of Laboratory Medicine, University of Minnesota Cancer Center, MMC 806, 420 Delaware St, Minneapolis, MN 55455, USA
    Immunol Res 38:149-64. 2007
  2. ncbi request reprint Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
  3. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
  4. ncbi request reprint Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
    Cancer Biother Radiopharm 19:11-23. 2004
  5. ncbi request reprint Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51
    Qing Yao
    The Cancer Center, University of Minnesota MMC 806, 420 Delaware St SE, Minneapolis, Minnesota, USA
    Clin Cancer Res 13:1591-600. 2007
  6. pmc A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy
    Weili Chen
    Cancer Center, University of Minnesota, Minneapolis, USA
    Blood 108:669-77. 2006
  7. ncbi request reprint Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia
    Jennifer J Johnson
    University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 101:3229-35. 2003
  8. pmc A role for MEIS1 in MLL-fusion gene leukemia
    Ashish R Kumar
    Masonic Cancer Center, Minneapolis, MN 55455, USA
    Blood 113:1756-8. 2009
  9. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
  10. ncbi request reprint Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology
    Inhua Muyrers-Chen
    ZMBH, University of Heidelberg, D 69120 Heidelberg, Germany
    Oncogene 23:8639-48. 2004

Research Grants

  1. Cancer Center Support Grant P30 CA77598-06
    John Kersey; Fiscal Year: 2006
  2. MLL AF4 LEUKEMIA
    John Kersey; Fiscal Year: 2007
  3. MLL AF4 LEUKEMIA
    John Kersey; Fiscal Year: 2004
  4. MLL AF4 LEUKEMIA
    John Kersey; Fiscal Year: 2009

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Blood and marrow transplantation: a perspective from the University of Minnesota
    John H Kersey
    Department of Laboratory Medicine, University of Minnesota Cancer Center, MMC 806, 420 Delaware St, Minneapolis, MN 55455, USA
    Immunol Res 38:149-64. 2007
    ..My affection for Bob Good and Bill Krivit is unending...
  2. ncbi request reprint Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
    ..7 x 10(5) CD34(+) cells per kilogram of recipient's body weight. Therefore, graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less...
  3. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
    ..To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG)...
  4. ncbi request reprint Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody
    Daniel A Vallera
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Cancer Center, Minneapolis, MN, USA
    Cancer Biother Radiopharm 19:11-23. 2004
    ..Because radiolabeled anti-CD19 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data support the use of 90Y anti-CD19 antibodies in treating B-cell malignancies...
  5. ncbi request reprint Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51
    Qing Yao
    The Cancer Center, University of Minnesota MMC 806, 420 Delaware St SE, Minneapolis, Minnesota, USA
    Clin Cancer Res 13:1591-600. 2007
    ..In this study, we evaluated the effects of etoposide and 17-AAG in leukemia cells and the roles of Hsp90, FMS-like tyrosine kinase 3 (FLT3), checkpoint kinase 1 (Chk1), Rad51, and topoisomerase II in this inhibition...
  6. pmc A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy
    Weili Chen
    Cancer Center, University of Minnesota, Minneapolis, USA
    Blood 108:669-77. 2006
    ..The molecular basis for "instruction" and secondary cooperating mutations can now be studied in our Mll-AF4 model...
  7. ncbi request reprint Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia
    Jennifer J Johnson
    University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Blood 101:3229-35. 2003
    ....
  8. pmc A role for MEIS1 in MLL-fusion gene leukemia
    Ashish R Kumar
    Masonic Cancer Center, Minneapolis, MN 55455, USA
    Blood 113:1756-8. 2009
    ..Targeting MEIS1 may have therapeutic potential for treating leukemias expressing this transcription factor...
  9. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
    ..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care...
  10. ncbi request reprint Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology
    Inhua Muyrers-Chen
    ZMBH, University of Heidelberg, D 69120 Heidelberg, Germany
    Oncogene 23:8639-48. 2004
    ..Taken together, the expression of MLL fusion proteins in Drosophila provides a new and powerful system to reveal and characterize biological activities associated with MLL fusion proteins...

Research Grants10

  1. Cancer Center Support Grant P30 CA77598-06
    John Kersey; Fiscal Year: 2006
    ..abstract_text> ..
  2. MLL AF4 LEUKEMIA
    John Kersey; Fiscal Year: 2007
    ..Consideration will be given to HOXA cluster, MEIS1 or MLL fusion genes as potential therapeutic targets. ..
  3. MLL AF4 LEUKEMIA
    John Kersey; Fiscal Year: 2004
    ..2) To evaluate the hypothesis that the effects of MLL-AF4 fusion gene are cell-type specific. (3) To study mice with MLL-AF4 or MLL-AF9 fusion gene leukemia. ..
  4. MLL AF4 LEUKEMIA
    John Kersey; Fiscal Year: 2009
    ..Consideration will be given to HOXA cluster, MEIS1 or MLL fusion genes as potential therapeutic targets. ..